AtriCure Statistics
Total Valuation
AtriCure has a market cap or net worth of $2.04 billion. The enterprise value is $1.95 billion.
| Market Cap | 2.04B |
| Enterprise Value | 1.95B |
Important Dates
The last earnings date was Thursday, July 23, 2026, after market close.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AtriCure has 50.87 million shares outstanding. The number of shares has increased by 2.50% in one year.
| Current Share Class | 50.87M |
| Shares Outstanding | 50.87M |
| Shares Change (YoY) | +2.50% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | 4.11% |
| Owned by Institutions (%) | 101.17% |
| Float | 48.77M |
Valuation Ratios
The trailing PE ratio is 190.44 and the forward PE ratio is 163.28.
| PE Ratio | 190.44 |
| Forward PE | 163.28 |
| PS Ratio | 3.59 |
| Forward PS | 3.18 |
| PB Ratio | 3.95 |
| P/TBV Ratio | 8.57 |
| P/FCF Ratio | 38.45 |
| P/OCF Ratio | 31.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 57.75, with an EV/FCF ratio of 36.69.
| EV / Earnings | 184.68 |
| EV / Sales | 3.42 |
| EV / EBITDA | 57.75 |
| EV / EBIT | 151.18 |
| EV / FCF | 36.69 |
Financial Position
The company has a current ratio of 4.22, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.22 |
| Quick Ratio | 3.02 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 2.20 |
| Debt / FCF | 1.40 |
| Interest Coverage | 2.29 |
Financial Efficiency
Return on equity (ROE) is 2.15% and return on invested capital (ROIC) is 2.67%.
| Return on Equity (ROE) | 2.15% |
| Return on Assets (ROA) | 1.25% |
| Return on Invested Capital (ROIC) | 2.67% |
| Return on Capital Employed (ROCE) | 2.17% |
| Weighted Average Cost of Capital (WACC) | 10.95% |
| Revenue Per Employee | $421,942 |
| Profits Per Employee | $7,816 |
| Employee Count | 1,350 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 1.68 |
Taxes
In the past 12 months, AtriCure has paid $1.54 million in taxes.
| Income Tax | 1.54M |
| Effective Tax Rate | 12.75% |
Stock Price Statistics
The stock price has increased by +26.54% in the last 52 weeks. The beta is 1.25, so AtriCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | +26.54% |
| 50-Day Moving Average | 30.87 |
| 200-Day Moving Average | 33.13 |
| Relative Strength Index (RSI) | 73.28 |
| Average Volume (20 Days) | 938,572 |
Short Selling Information
The latest short interest is 4.86 million, so 9.56% of the outstanding shares have been sold short.
| Short Interest | 4.86M |
| Short Previous Month | 4.45M |
| Short % of Shares Out | 9.56% |
| Short % of Float | 9.97% |
| Short Ratio (days to cover) | 4.62 |
Income Statement
In the last 12 months, AtriCure had revenue of $569.62 million and earned $10.55 million in profits. Earnings per share was $0.21.
| Revenue | 569.62M |
| Gross Profit | 434.61M |
| Operating Income | 12.89M |
| Pretax Income | 12.09M |
| Net Income | 10.55M |
| EBITDA | 33.75M |
| EBIT | 12.89M |
| Earnings Per Share (EPS) | $0.21 |
Balance Sheet
The company has $167.79 million in cash and $74.22 million in debt, with a net cash position of $93.57 million or $1.84 per share.
| Cash & Cash Equivalents | 167.79M |
| Total Debt | 74.22M |
| Net Cash | 93.57M |
| Net Cash Per Share | $1.84 |
| Equity (Book Value) | 516.43M |
| Book Value Per Share | 10.15 |
| Working Capital | 263.62M |
Cash Flow
In the last 12 months, operating cash flow was $64.94 million and capital expenditures -$11.83 million, giving a free cash flow of $53.11 million.
| Operating Cash Flow | 64.94M |
| Capital Expenditures | -11.83M |
| Depreciation & Amortization | 20.86M |
| Net Borrowing | 4.10M |
| Free Cash Flow | 53.11M |
| FCF Per Share | $1.04 |
Margins
Gross margin is 76.30%, with operating and profit margins of 2.26% and 1.85%.
| Gross Margin | 76.30% |
| Operating Margin | 2.26% |
| Pretax Margin | 2.12% |
| Profit Margin | 1.85% |
| EBITDA Margin | 5.92% |
| EBIT Margin | 2.26% |
| FCF Margin | 9.32% |
Dividends & Yields
AtriCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.50% |
| Shareholder Yield | -2.50% |
| Earnings Yield | 0.52% |
| FCF Yield | 2.60% |
Analyst Forecast
The average price target for AtriCure is $47.33, which is 17.88% higher than the current price. The consensus rating is "Buy".
| Price Target | $47.33 |
| Price Target Difference | 17.88% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 12.67% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AtriCure has an Altman Z-Score of 6.77 and a Piotroski F-Score of 8.
| Altman Z-Score | 6.77 |
| Piotroski F-Score | 8 |